Overview

Reversal of Ventricular Remodeling With Toprol-XL

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Metoprolol
Criteria
Inclusion Criteria:

- Diagnosis of stable asymptomatic heart failure.

- Documented ejection fraction less than 0.40.

- Must be able to comply with all study procedures.

Exclusion Criteria:

- Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization.

- Have heart problems that would not allow B-blocker therapy.

- Receiving B-blockers therapy for any medical reason including topical B-blockers that
might cause systemic absorption (e.g., glaucoma).

- Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.

- Have certain heart diseases.

- Pregnant or breast feeding.

- Unlikely to survive.